市場調査レポート

商品コード

1624386

インフルエンザ診断の世界市場規模：製品別、エンドユーザー別、検査タイプ別、地域別、範囲および予測

Global Influenza Diagnostics Market Size By Product (test kits and reagents, instruments), By End User (diagnostics laboratories, hospitals & clinic), By Test Type (traditional test, molecular diagnostic assay), By Geographic Scope And Forecast

出版日: 2024年09月28日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日

価格

PDF (Single User License)

USD 3,950 569,037円

1名のみが、レポートにアクセスする事ができるライセンスです。レポートPDFのダウンロード、印刷は可能です。

PDF & Excel (5 User License)

USD 4,850 698,691円

5名までが、レポートにアクセスする事ができるライセンスです。レポートPDF・関連するExcelシートのダウンロード、印刷は可能です。

PDF & Excel (Enterprise User License)

USD 7,550 1,087,653円

人数制限なく、レポートにアクセスできるライセンスです。PDF形式のレポートと関連するExcel出力シートの両方をダウンロード、印刷する事が可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

インフルエンザ診断の市場規模と予測

インフルエンザ診断の市場規模は、2024年には8億4,000万米ドルで、2031年には15億6,000万米ドルに達すると予測され、2024年から2031年までのCAGRは9.00%で成長します。一般にインフルエンザとして知られるインフルエンザは、インフルエンザウイルスによって引き起こされる感染症です。インフルエンザの同定・診断には、様々な従来技術や分子診断技術が用いられています。逆転写ポリメラーゼ連鎖反応やリアルタイム分子検査は、インフルエンザの遺伝物質の検出を可能にします。インフルエンザの迅速診断検査は進歩し続けており、迅速な結果とサンプル採取の容易さから、この方法は診断に有効です。インフルエンザの流行の増加、特定の診断検査を用いた早期発見に対する意識の高まり、中央集中型の検査室から分散型のポイントオブケア検査への重点のシフトといった要因が、世界のインフルエンザ診断市場の成長を促進すると予想されます。

さらに、慢性疾患の有病率の増加、高齢者人口の増加、インフルエンザを監視するための政府のイニシアチブの増加、および技術的に高度なインフルエンザ診断検査の開発により、インフルエンザ診断に対する需要は増加すると思われます。

ポイント・オブ・ケア技術とインフルエンザ検査の統合など、技術的に進歩した新しいインフルエンザ診断検査は、老年人口におけるサーベイランス・プロセスを促進すると予想されます。さらに、ポイントオブケア技術は、医療へのアクセスが限られているアジア太平洋地域の農村部でのインフルエンザ検査を増加させることが期待されます。

しかし、検査や機器の開発コストが市場開拓の妨げになる可能性があります。原材料の入手性や入手しやすさの制約が、製品の総コストを上昇させる。高い製造コストの負担は、高価格としてエンドユーザーに転嫁されます。

インフルエンザ診断の世界市場力学

主な市場促進要因

インフルエンザの負担の増大：

世界の季節性インフルエンザの流行は、重大な疾病、入院、死亡を引き起こし、迅速かつ正確な診断技術の必要性を強調しています。これらのツールは、治療を決定し、効果的な管理対策を実施するために不可欠です。

ヘルスケアに対する意識の高まり：

インフルエンザとその影響に対する一般市民の意識が高まるにつれ、迅速で簡便な診断検査に対する需要が高まっています。この開発は、健康管理に対する積極的な姿勢を表しており、人々は簡単に利用できる診断ソリューションを求めています。

技術の進歩：

高速分子アッセイ、ポイント・オブ・ケア検査、マルチプレックス・アッセイなどの新技術が、インフルエンザ診断に変革をもたらしつつあります。これらの進歩により、スピードや精度が向上し、同時に多くのインフルエンザ株を同定できるようになったため、診断能力が向上しています。

早期発見と治療の重視：

インフルエンザの早期治療と合併症の予防には、早期発見・早期治療が重要です。迅速な診断検査により、抗ウイルス薬による早期治療が可能となり、患者の転帰を改善し、ヘルスケアコストを削減することができます。

拡大する老年人口

世界人口の高齢化に伴い、高齢者は特にインフルエンザに関連した問題を起こしやすくなっています。この人口動態の変化は、高齢者の需要に適応した、信頼性が高く、簡便に利用できる診断検査の重要性を浮き彫りにしています。

生物脅威への備え：

インフルエンザウイルスはパンデミックを引き起こす可能性があるため、生物脅威への備えと対応活動には迅速で正確な診断技術が必要です。効果的な診断法は、アウトブレイクを抑制し、その被害を最小限に抑えるために不可欠です。

政府の取り組みと償還政策：

いくつかの政府は、インフルエンザのワクチン接種と診断を促進するための公衆衛生イニシアチブを開始しています。さらに、インフルエンザ診断検査に対する有利な支払規定は、アクセシビリティを高め、これらの重要な機器の普及を促進する上で重要な役割を果たしています。

主な課題

検査の感度と特異度のばらつき：

特に迅速検査では、検査性能にばらつきがあるため、インフルエンザと他の呼吸器感染症との鑑別が正しく行われず、誤診や不適切な治療の推奨につながる可能性があります。

高度な検査はコストが高い：

分子アッセイのような高度な技術は、より高い精度を提供するが、その分コストも高くなるため、特にヘルスケア予算が限られている資源の乏しい地域では、アクセスが制限されます。

標準化の欠如：

性能特性が異なる複数のインフルエンザ診断検査が普及しているため、検査結果の解釈や比較が複雑になり、医療従事者に不確実性をもたらし、患者の効果的な治療方針の決定を妨げています。

遠隔地での限られた利用可能性：

遠隔地や低所得地域では、高度な診断検査へのアクセスが制限されているため、診断や治療が遅れ、特に、高度な検査機能を備えたヘルスケア施設にアクセスする障壁に直面している社会的弱者にとってはその傾向が強いです。

熟練した人材の不足：

最新のインフルエンザ診断検査の中には、正しく操作し、解釈するために特別な訓練や技術を必要とするものがあります。このような検査が利用できる場合でも、特定の場所では有能な人材が不足しているため、効果的に利用することができません。

診療報酬の問題：

インフルエンザ診断に対する償還規制が不十分であるため、ヘルスケアプロバイダーが新しい技術を採用できず、市場全体の成長と改良型検査の利用が制限される可能性があります。

偽陽性と偽陰性：

改善されたとはいえ、一部の検査では偽陽性や偽陰性の結果が出ることがあり、その結果、無駄な治療、資源の浪費、患者の不安を招き、検査手法の有効性と費用効率が損なわれます。

進化するウイルス株：

インフルエンザウイルスは常に変化しており、診断法を成功させ続けるためには、継続的な更新と変更が必要です。新型ウイルス株のイントロダクションは、正確で信頼性の高い診断システムを維持する上で、診断薬メーカーの出費とハードルを増加させる可能性があります。

主な動向

迅速診断検査の採用：

インフルエンザ迅速診断検査（RIDT）は、その利便性、迅速性、使いやすさにより、診療時点における迅速な治療方針の決定を可能にするため、ますます普及しつつあります。

マルチプレックス・アッセイの出現：

マルチプレックスアッセイは、インフルエンザウイルスやRSVなど多数の呼吸器感染症を1回の検査で検出できるため、効率が向上し、複数の検査を行う必要がなくなるため、普及しつつあります。

ポイントオブケア検査（POCT）への注力：

業界は、インフルエンザ診断のためのPOCT（ポイント・オブ・ケア）検査ソリューションの開発へとシフトしており、これにより、診療所、薬局、家庭など、さまざまな場所で携帯可能で使い勝手のよいオプションが提供されることになります。

遠隔医療プラットフォームとの統合：

インフルエンザ診断検査は、遠隔医療プラットフォームと急速に接続されつつあり、遠隔診断や診察が可能になるため、特に恵まれない地域でのヘルスケアアクセスが向上します。

分子診断の技術的進歩：

技術の進歩に伴い、インフルエンザ診断のための、より高感度で特異的な分子アッセイが開発されつつあり、異なるインフルエンザ株の鑑別が可能になり、的を絞った治療戦略やワクチン開発に役立っています。

人工知能の統合：

人工知能（AI）アルゴリズムがインフルエンザ診断に統合され、診断検査のデータ解析により、精度の向上、新型株の特定、流行の予測が可能になりつつあります。

在宅検査の重視：

COVID-19の大流行により、在宅診断検査への需要が高まっており、使いやすい自己検査キットの進歩により、インフルエンザ診断にも同様の動向が予測されます。

世界のインフルエンザ診断市場概要
インフルエンザ診断の世界：絶対的収益機会
インフルエンザ診断の世界市場の魅力：地域別
インフルエンザ診断の世界市場の魅力：製品別
インフルエンザ診断の世界市場の魅力：エンドユーザー別
インフルエンザ診断の世界市場の魅力：検査タイプ別
インフルエンザ診断の世界市場分析：地域別
インフルエンザ診断の世界市場：製品別
インフルエンザ診断の世界市場：エンドユーザー別
インフルエンザ診断の世界市場：検査タイプ別
今後の市場機会
世界市場内訳

第4章市場展望

インフルエンザ診断世界市場の変遷
インフルエンザ診断世界市場の展望
市場促進要因
- 診断技術のためのインフルエンザ研究の成長
- インフルエンザ流行の増加
抑制要因
- 未熟な専門家
- 厳しいFDA規制
可能性
- ゲノムおよびプロテオミクス技術の進歩
- 研究開発活動の増加
COVID-19が世界のインフルエンザ診断市場に与える影響
ポーターのファイブフォース分析
- 買い手の交渉力
- 供給企業の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競争企業間の敵対関係
バリューチェーン分析
マクロ経済分析

第5章エンドユーザー別市場

概要
診断ラボ
病院・診療所
その他

第6章製品別市場

概要
検査キットおよび試薬
検査機器
その他

第7章検査タイプ別市場

概要
従来型診断検査
- 迅速インフルエンザ診断検査（RIDT）
- ウイルス培養
- 直接蛍光抗体（DFA）検査
- 血清学的検査
分子診断検査
- RT-PCR法
- 核酸配列に基づく増幅（nasba）検査
- ループ媒介等温増幅法（lamp）
- 単純増幅法（サンバ）
- その他の分子診断アッセイ

第8章地域別市場

概要
北米
- 北米市場スナップショット
- 米国
- カナダ
- メキシコ
欧州
- 欧州市場スナップショット
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他欧州
アジア太平洋
- アジア太平洋市場スナップショット
- 中国
- 日本
- インド
- その他アジア太平洋地域
ラテンアメリカ
- ラテンアメリカ市場スナップショット
- ブラジル
- アルゼンチン
- その他ラテンアメリカ
中東・アフリカ
- 中東・アフリカ市場スナップショット
- アラブ首長国連邦
- サウジアラビア
- 南アフリカ
- その他中東とアフリカ

第9章競合情勢

概要
競合シナリオ
各社の市場ランキング分析
地域別フットプリント
企業の産業別フットプリント
エースマトリックス
- アクティブ
- カッティング・エッジ
- エマージング
- イノベーター

第10章企業プロファイル

ABBOTT LABORATORIES
THERMO FISHER SCIENTIFIC INC.
DANAHER CORPORATION
SIEMENS HEALTHINEERS AG
HOFFMANN-LA ROCHE AG
BECTON, DICKINSON, AND COMPANY
DIASORIN & LUMINEX CORPORATION
QUIDEL CORPORATION
CORIS BIOCONCEPT
ANALYTIK JENA AG（ENDRESS+HAUSER AG）
MERIDIAN BIOSCIENCE
SA SCIENTIFIC, LTD
SEKISUI DIAGNOSTIC
HOLOGIC INC.
3M
BIOMERIEUX SA
GENMARK DIAGNOSTICS INC.
ALTONA DIAGNOSTICS
ELITECH GROUP
MAST GROUP LTD
KONINKLIJKE PHILIPS N.V.
SYSMEX CORPORATION

図表

LIST OF TABLES

TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
TABLE 2 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 3 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 4 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 5 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY GEOGRAPHY, 2020-2030 (USD MILLION)
TABLE 6 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 7 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 8 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 9 NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 10 U.S. INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 11 U.S. INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 12 U.S. INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 13 CANADA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 14 CANADA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 15 CANADA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 16 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 17 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 18 MEXICO INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 19 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 20 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 21 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 22 EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 23 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 24 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 25 GERMANY INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 26 U.K. INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 27 U.K. INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 28 U.K. INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 29 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 30 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 31 FRANCE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 32 ITALY INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 33 ITALY INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 34 ITALY INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 35 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 36 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 37 SPAIN INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 38 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 39 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 40 REST OF EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 45 CHINA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 46 CHINA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 47 CHINA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 48 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 49 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 50 JAPAN INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 51 INDIA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 52 INDIA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 53 INDIA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 54 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 55 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 56 REST OF ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 57 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 58 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 59 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 60 LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 61 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 62 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 63 BRAZIL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 64 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 65 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 66 ARGENTINA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 67 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 68 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 69 REST OF LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 74 UAE INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 75 UAE INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 76 UAE INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 77 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 78 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 79 SAUDI ARABIA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 83 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END-USER, 2020-2030 (USD MILLION)
TABLE 84 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2020-2030 (USD MILLION)
TABLE 85 REST OF MIDDLE EAST AND AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020-2030 (USD MILLION)
TABLE 86 COMPANY MARKET RANKING ANALYSIS
TABLE 87 COMPANY REGIONAL FOOTPRINT
TABLE 88 COMPANY INDUSTRY FOOTPRINT
TABLE 89 ABBOTT LABORATORIES: PRODUCT BENCHMARKING
TABLE 90 ABBOTT LABORATORIES: KEY DEVELOPMENTS
TABLE 91 ABBOTT LABORATORIES: WINNING IMPERATIVES
TABLE 92 THERMO FISHER SCIENTIFIC INC.: PRODUCT BENCHMARKING
TABLE 93 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
TABLE 94 THERMO FISHER SCIENTIFIC INC.: WINNING IMPERATIVES
TABLE 95 DANAHER CORPORATION: PRODUCT BENCHMARKING
TABLE 96 DANAHER CORPORATION: WINNING IMPERATIVES
TABLE 97 SIEMENS HEALTHINEERS AG: PRODUCT BENCHMARKING
TABLE 98 SIEMENS HEALTHINEERS AG: KEY DEVELOPMENTS
TABLE 99 SIEMENS HEALTHINEERS AG: WINNING IMPERATIVES
TABLE 100 HOFFMANN-LA ROCHE AG: PRODUCT BENCHMARKING
TABLE 101 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS
TABLE 102 HOFFMANN-LA ROCHE AG: WINNING IMPERATIVES
TABLE 103 BECTON, DICKINSON, AND COMPANY: PRODUCT BENCHMARKING
TABLE 104 BECTON, DICKINSON, AND COMPANY (BD): KEY DEVELOPMENTS
TABLE 105 DIASORIN: PRODUCT BENCHMARKING
TABLE 106 DIASORIN: KEY DEVELOPMENTS
TABLE 107 LUMINEX CORPORATION: PRODUCT BENCHMARKING
TABLE 108 QUIDEL CORPORATION: PRODUCT BENCHMARKING
TABLE 109 QUIDEL CORPORATION: KEY DEVELOPMENTS
TABLE 110 CORIS BIOCONCEPT: PRODUCT BENCHMARKING
TABLE 111 ANALYTIK JENA AG (ENDRESS+HAUSER AG): PRODUCT BENCHMARKING
TABLE 112 MERIDIAN BIOSCIENCS: PRODUCT BENCHMARKING
TABLE 113 SA SCIENTIFIC: PRODUCT BENCHMARKING
TABLE 114 SEKISUI DIAGNOSTICS: PRODUCT BENCHMARKING
TABLE 115 SEKISUI DIAGNOSTICS.: KEY DEVELOPMENTS
TABLE 116 HOLOGIC INC.: PRODUCT BENCHMARKING
TABLE 117 HOLOGIC INC.: KEY DEVELOPMENTS
TABLE 118 3M: PRODUCT BENCHMARKING
TABLE 119 BIOMERIEUX S. A.: PRODUCT BENCHMARKING
TABLE 120 GENMARK DIAGNOSTICS, INC..: PRODUCT BENCHMARKING
TABLE 121 ALTONA DIAGNOSTICS: PRODUCT BENCHMARKING
TABLE 122 ALTONA DIAGNOSTICS: KEY DEVELOPMENT
TABLE 123 ELITECH GROUP: PRODUCT BENCHMARKING
TABLE 124 MAST GROUP LTD: PRODUCT BENCHMARKING
TABLE 125 KONINKLIJKE PHILIPS N.V.: PRODUCT BENCHMARKING

LIST OF FIGURES

FIGURE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2 RESEARCH TIMELINES
FIGURE 3 DATA TRIANGULATION
FIGURE 4 MARKET RESEARCH FLOW
FIGURE 5 DATA SOURCES
FIGURE 6 GLOBAL INFLUENZA DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
FIGURE 7 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
FIGURE 8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER (USD MILLION)
FIGURE 9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION)
FIGURE 10 FUTURE MARKET OPPORTUNITIES
FIGURE 11 TRADITIONAL DIAGNOSTIC TEST SEGMENT DOMINATED THE MARKET IN 2021
FIGURE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
FIGURE 13 PORTER'S FIVE FORCES ANALYSIS
FIGURE 14 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END-USER
FIGURE 15 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT
FIGURE 16 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE
FIGURE 17 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY GEOGRAPHY, 2020-2030 (USD MILLION)
FIGURE 18 U.S. MARKET SNAPSHOT
FIGURE 19 CANADA MARKET SNAPSHOT
FIGURE 20 MEXICO MARKET SNAPSHOT
FIGURE 21 GERMANY MARKET SNAPSHOT
FIGURE 22 U.K. MARKET SNAPSHOT
FIGURE 23 FRANCE MARKET SNAPSHOT
FIGURE 24 ITALY MARKET SNAPSHOT
FIGURE 25 SPAIN MARKET SNAPSHOT
FIGURE 26 REST OF EUROPE MARKET SNAPSHOT
FIGURE 27 CHINA MARKET SNAPSHOT
FIGURE 28 JAPAN MARKET SNAPSHOT
FIGURE 29 INDIA MARKET SNAPSHOT
FIGURE 30 REST OF ASIA PACIFIC MARKET SNAPSHOT
FIGURE 31 BRAZIL MARKET SNAPSHOT
FIGURE 32 ARGENTINA MARKET SNAPSHOT
FIGURE 33 REST OF LATIN AMERICA MARKET SNAPSHOT
FIGURE 34 UAE MARKET SNAPSHOT
FIGURE 35 SAUDI ARABIA MARKET SNAPSHOT
FIGURE 36 SOUTH AFRICA MARKET SNAPSHOT
FIGURE 37 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
FIGURE 38 KEY STRATEGIC DEVELOPMENTS
FIGURE 39 ACE MATRIC
FIGURE 40 ABBOTT LABORATORIES: COMPANY INSIGHT
FIGURE 41 ABBOTT LABORATORIES: BREAKDOWN
FIGURE 42 ABBOTT LABORATORIES: SWOT ANALYSIS
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY INSIGHT
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: BREAKDOWN
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 46 DANAHER CORPORATION: COMPANY INSIGHT
FIGURE 47 DANAHER CORPORATION: BREAKDOWN
FIGURE 48 DANAHER CORPORATION: SWOT ANALYSIS
FIGURE 49 SIEMENS HEALTHINEERS AG.: COMPANY INSIGHT
FIGURE 50 SIEMENS HEALTHINEERS AG: SEGMENT BREAKDOWN
FIGURE 51 SIEMENS HEALTHINEERS AG: SWOT ANALYSIS
FIGURE 52 HOFFMANN-LA ROCHE AG: COMPANY INSIGHT
FIGURE 53 HOFFMANN-LA ROCHE AG: BREAKDOWN
FIGURE 54 HOFFMANN-LA ROCHE AG: SWOT ANALYSIS
FIGURE 55 BECTON, DICKINSON, AND COMPANY: COMPANY INSIGHT
FIGURE 56 BECTON, DICKINSON, AND COMPANY: BREAKDOWN
FIGURE 57 DIASORIN & LUMINEX CORPORATION: COMPANY INSIGHT
FIGURE 58 DIASORIN & LUMINEX CORPORATION: BREAKDOWN
FIGURE 59 QUIDEL CORPORATION: COMPANY INSIGHT
FIGURE 60 QUIDEL CORPORATION: BREAKDOWN
FIGURE 61 CORIS BIOCONCEPT: COMPANY INSIGHT
FIGURE 62 ANALYTIK JENA AG (ENDRESS+HAUSER AG): COMPANY INSIGHT
FIGURE 63 ANALYTIK JENA AG (ENDRESS+HAUSER AG): BREAKDOWN
FIGURE 64 MERIDIAN BIOSCIENCES: COMPANY INSIGHT
FIGURE 65 MERIDIAN BIOSCIENCES: BREAKDOWN
FIGURE 66 SA SCIENTIFIC: COMPANY INSIGHT
FIGURE 67 SEKISUI DIAGNOSTIC: COMPANY INSIGHT
FIGURE 68 HOLOGIC INC: COMPANY INSIGHT
FIGURE 69 HOLOGIC INC: SEGMENT BREAKDOWN
FIGURE 70 3M.: COMPANY INSIGHT
FIGURE 71 3M: SEGMENT BREAKDOWN
FIGURE 72 BIOMERIEUX S. A.: COMPANY INSIGHT
FIGURE 73 BIOMERIEUX S. A.: BREAKDOWN
FIGURE 74 GENMARK DIAGNOSTICS INC.: COMPANY INSIGHT
FIGURE 75 ALTONA DIAGNOSTICS.: COMPANY INSIGHT
FIGURE 76 ELITECH GROUP: COMPANY INSIGHT
FIGURE 77 MAST GROUP LTD: COMPANY INSIGHT
FIGURE 78 KONINKLIJKE PHILIPS N.V: COMPANY INSIGHT
FIGURE 79 KONINKLIJKE PHILIPS N.V: SEGMENT BREAKDOWN
FIGURE 80 SYSMEX CORPORATION.: COMPANY INSIGHT
FIGURE 81 SYSMEX CORPORATION.: SEGMENT BREAKDOWN

Product Code: 24117

Influenza Diagnostics Market Size And Forecast

Influenza Diagnostics Market size was valued at USD 0.84 Billion in 2024 and is projected to reach USD 1.56 Billion by 2031 , growing at a CAGR of 9.00% from 2024 to 2031. Influenza, commonly known as the flu, is an infection caused by the influenza virus. A variety of traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Reverse transcription-polymerase chain reaction and real-time molecular testing allows the detection of influenza genetic material. Continued advances in rapid influenza diagnostic testing have made this method effective for diagnosis due to its rapid results and ease of sample collection. Factors such as the increasing prevalence of influenza, increasing awareness of early detection using specific diagnostic tests, and a shift in focus from centralized laboratories to decentralized point-of-care testing are expected to drive the growth of the global influenza diagnostics market.

Additionally, due to the increasing prevalence of chronic diseases, the growing geriatric population, increasing government initiatives to monitor influenza, and the development of technologically advanced diagnostic tests for influenza, the demand for influenza diagnostics is likely to increase.

Emerging technologically advanced influenza diagnostic tests, including integration of point-of-care technology and influenza testing, are expected to facilitate the surveillance process in the geriatric population. In addition, point-of-care technology is expected to increase influenza testing in rural areas of the Asia-Pacific region, where access to health care is limited.

However, the cost of test and equipment development may hamper the market growth. Raw material availability and accessibility constraints increase the total cost of the product. The burden of high production costs is passed on to end users at high prices.

Global Influenza Diagnostics Market Dynamics

The key market dynamics that are shaping the global influenza diagnostics market include:

Key Market Drivers

Escalating Burden of Influenza:

Global seasonal influenza outbreaks cause significant sickness, hospitalizations, and deaths, emphasizing the need for rapid and precise diagnostic techniques. These tools are critical for making treatment decisions and carrying out effective management measures.

Increased Healthcare Awareness:

As the public becomes more aware of influenza and its repercussions, there is a greater demand for quick and simple diagnostic testing. This development represents a proactive attitude to health management, with people seeking easily accessible diagnostic solutions.

Advancements in Technology:

Novel technologies including as fast molecular assays, point-of-care tests, and multiplex assays are transforming influenza diagnostics. These advancements improve speed, accuracy, and the ability to identify many influenza strains at the same time, hence increasing diagnostic capabilities.

Emphasis on Early Detection and Treatment:

Early detection and treatment are crucial for early treatment and preventing complications from influenza. Rapid diagnostic tests allow for early intervention with antiviral drugs, which improves patient outcomes and reduces healthcare costs.

Expanding Geriatric Population

: As the world population ages, the elderly are especially vulnerable to influenza-related problems. This demographic transition highlights the importance of reliable and conveniently accessible diagnostic testing adapted to the demands of older persons.

Biothreat Preparedness:

Influenza viruses have the potential to cause pandemics, hence rapid and accurate diagnostic technologies are required for biothreat preparedness and response operations. Effective diagnostics are critical for limiting outbreaks and minimizing their damage.

Government Initiatives and Reimbursement Policies:

Several governments are launching public health initiatives to promote influenza vaccination and diagnosis. Furthermore, favorable payment rules for influenza diagnostic tests play an important role in increasing accessibility and encouraging widespread usage of these critical instruments.

Key Challenges:

Variability in Test Sensitivity and Specificity:

Inconsistencies in test performance, especially with quick testing, can lead to incorrect discrimination between influenza and other respiratory infections, resulting in misdiagnosis and poor treatment recommendations.

High Cost of Advanced Tests:

Advanced technologies such as molecular assays provide greater precision but come at a higher cost, limiting access, particularly in resource-constrained regions with restricted healthcare budgets.

Lack of Standardization:

The prevalence of several influenza diagnostic tests with differing performance characteristics complicates interpreting and comparing results across tests, causing uncertainty for healthcare practitioners and impeding effective patient treatment decisions.

Limited Availability in Remote Areas:

Access to advanced diagnostic tests is limited in distant or low-income areas, delaying diagnosis and treatment, especially for vulnerable groups that face barriers to accessing healthcare facilities with advanced testing capabilities.

Limited Skilled Personnel:

Certain modern influenza diagnostic tests necessitate specific training and skills to operate and interpret correctly. Even when these tests are available, a lack of competent workers in certain places prevents them from being used effectively.

Reimbursement Issues:

Inadequate reimbursement regulations for influenza diagnostics may prevent healthcare providers from adopting newer technologies, limiting overall market growth and the availability of improved tests.

False Positives and Negatives:

Despite improvements, some tests continue to provide false positive or negative results, resulting in wasteful treatments, resource waste, and patient worry, compromising the effectiveness and cost-efficiency of testing methodologies.

Evolving Viral Strains:

Influenza viruses are constantly changing, demanding ongoing updates and changes to diagnostic procedures in order to remain successful. The introduction of novel virus strains may result in increased expenditures and hurdles for diagnostic manufacturers in maintaining accurate and trustworthy diagnostic systems.

Key Trends:

Adoption of Rapid Diagnostic Tests:

Rapid influenza diagnostic tests (RIDTs) are becoming increasingly popular because to their convenience, speed, and ease of use, allowing for swift treatment decisions at the point of care.

Emergence of Multiplex Assays:

Multiplex assays are becoming popular because they may detect numerous respiratory infections, such as influenza viruses and RSV, in a single test, increasing efficiency and eliminating the need for multiple tests.

Focus on Point-of-Care Testing (POCT):

The industry is shifting toward developing point-of-care testing (POCT) solutions for influenza diagnostics, which will provide portable and user-friendly options for a variety of locations, including clinics, pharmacies, and homes.

Integration with Telehealth Platforms:

Influenza diagnostic tests are rapidly being connected with telehealth platforms, allowing for remote diagnosis and consultation, hence enhancing healthcare access, particularly in underprivileged areas.

Technological Advances in Molecular Diagnostics:

As technology advances, more sensitive and specific molecular assays for influenza diagnosis are being developed, allowing for differentiation between different influenza strains and aiding in targeted treatment strategies and vaccine development.

Integration of Artificial Intelligence:

Artificial intelligence (AI) algorithms are being integrated into influenza diagnostics to improve accuracy, identify new strains, and anticipate epidemics by using diagnostic test data analysis.

Growing Emphasis on Home-Based Testing:

The COVID-19 pandemic has increased demand for home-based diagnostic tests, and similar trends are projected for influenza diagnostics, as advances in user-friendly self-testing kits become more widely available.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Influenza Diagnostics Market Regional Analysis

Here is a more detailed regional analysis of the global influenza diagnostics market:

North America

North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership.

The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

North America routinely devotes a high portion of its GDP to healthcare spending, allowing for major investment in healthcare technologies such as influenza diagnostics. The availability of large financial resources encourages the use of modern diagnostic tests and promotes market expansion in the region.

Each year, North America suffers significant seasonal influenza outbreaks, which cause a significant illness burden and public health impact. The incidence of influenza increases the demand for speedy and accurate diagnostic tests to guide treatment decisions, implement control measures, and limit disease spread, supporting the region's dominant position in the influenza diagnostics market.

Many of the world's largest influenza diagnostic firms, including those that make fast tests, molecular assays, and point-of-care devices, have their headquarters or a significant presence in North America. These companies use the region's superior infrastructure, research capabilities, and regulatory framework to develop and deliver breakthrough diagnostic solutions, reinforcing North America's market leadership.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the influenza diagnostics The Asia Pacific area is undergoing rapid economic expansion, which has coincided with advancements in healthcare infrastructure and access to medical services. Rising disposable incomes and government investments in healthcare drive up demand for diagnostic tests, especially those for influenza.

As Asia Pacific countries invest more in healthcare infrastructure and services, healthcare spending rises. This increasing investment promotes the use of innovative diagnostic technologies, hence driving growth in the influenza diagnostics market.

The Asia Pacific region's public is becoming more aware of infectious diseases, particularly influenza. Increased awareness generates more demand for diagnostic testing, particularly during influenza seasons, which contributes to market growth.

The Asia Pacific region has a vast and fast expanding population, especially in cities. Increased population density raises the risk of influenza transmission, driving up need for diagnostic tests to monitor and manage illness spread.

Countries in the Asia Pacific area are increasingly adopting innovative healthcare technologies, such as telemedicine platforms and point-of-care diagnostic devices. These technologies provide access to healthcare services and enable faster detection and treatment of influenza, resulting in market growth.

The COVID-19 pandemic has expedited the deployment of telehealth platforms throughout the Asia Pacific. The integration of influenza diagnostic tests with telehealth services allows for remote consultations and testing, increasing access to diagnostic services and driving market growth.

Global Influenza Diagnostics Market: Segmentation Analysis

The Global Influenza Diagnostics Market is segmented based on Product, End-User, Test Type, And Geography.

Influenza Diagnostics Market, By Product

Test kits and reagents.
Instruments
Others

Based on Product, the market is segmented into test kits and reagents, instruments, and others. Test kits and reagents dominate the Influenza Diagnostics Market, accounting for almost 60% of the total market share. This is due to a variety of causes, including its widespread availability through pharmacies, clinics, and internet sellers, frequently without the requirement for a prescription. These test kits are popular because they are simple to use; many are developed for point-of-care settings and require little training to administer. Furthermore, their low cost in comparison to other instruments makes them affordable to those with a variety of budgets. Given the importance of early influenza detection, these kits meet a significant need by offering a quick and accessible testing alternative. Furthermore, their versatility enables them to serve both healthcare professionals and those seeking self-testing choices at home.

Influenza Diagnostics Market, By End-User

Diagnostics laboratories
Hospitals & Clinic
Others

Based on End-users, the Global Influenza Diagnostics Market has been segmented into diagnostics laboratories, hospitals & clinics, and others. Hospitals and Clinics dominate the Influenza Diagnostics Market, owing to a number of important considerations. For starters, hospitals face a larger disease load, with a greater number of patients presenting with influenza-like symptoms, demanding frequent testing to ensure correct diagnosis and treatment decisions. Second, hospitals often have advanced testing capabilities, including access to a wide range of diagnostic tools and sophisticated apparatus, allowing for more precise and extensive testing procedures. Furthermore, hospitals have strong infrastructure and specialized people, such as dedicated laboratory facilities and trained experts who can successfully handle and interpret influenza diagnostic tests. Given the importance of prompt and correct diagnosis in patient treatment, hospitals prioritize diagnostic accuracy and efficiency. Furthermore, hospitals play an important role in public health surveillance by reporting influenza cases, relying on dependable diagnostic results to inform public health interventions and strategies.

Influenza Diagnostics Market, By Test Type

Traditional Test
Molecular Diagnostic Assay

Based on Test Type, the Global Influenza Diagnostics Market is classified into traditional tests and molecular diagnostic assay. While the Influenza Diagnostics Market is moving, traditional tests, such as Rapid Influenza Diagnostic Tests (RIDTs), continue to hold the majority share, accounting for around 66.7%. This is mostly due to various variables. First and foremost, traditional tests are less expensive than molecular assays, making them more accessible in a variety of healthcare settings. Furthermore, many traditional tests, particularly RIDTs, provide speedy results at the point of care, allowing for timely treatment options. Furthermore, their ease of use, with no administration training, makes them appropriate for widespread deployment in clinics and even self-testing. Given the high prevalence of influenza A and B, standard tests can detect the most common influenza strains, meeting a major amount of diagnostic needs. Moreover, the frequent use of traditional testing over a longer period has solidified their position in healthcare settings, contributing to their continued dominance in the market.

Influenza Diagnostics Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the Global Influenza Diagnostics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is significantly dominating the influenza diagnostics market and is expected to continue its growth throughout the forecast period, owing to several variables. North America has a well-developed healthcare infrastructure that includes cutting-edge medical facilities, advanced laboratories, and a qualified workforce. This infrastructure facilitates the effective diagnosis and management of influenza patients, which contributes to the region's market leadership. The region is home to leading pharmaceutical businesses, diagnostic manufacturers, and research organizations focused on improving influenza diagnostics. Ongoing research and development activities are aimed at inventing new diagnostic technologies, improving test accuracy, and increasing testing accessibility, thereby cementing North America's position as a dominating market participant.

Key Players

The "Global Influenza Diagnostics Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
Abbott Laboratories, F. Hoffmann-La Roche Ltd. (Roche Diagnostics), Danaher Corporation (Beckton Dickinson), Abbott Laboratories (Alere), Siemens Healthineers AG, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD Diagnostics), Meril Diagnostics Pvt. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and QIAGEN.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In May 2021, FDA approval has been received by Becton, Dickinson, and Company which is a medical technology company for the BD Veritor Plus System. The BD Veritor Plus System will play a vital role in detecting influenza A, influenza B, and SARS-CoV-2.
In March 2021, Emergency Use Authorization (EUA) was received from FDA for a laboratory PCR assay that will be beneficial in detecting and differentiating SARS-COV-2, RSV flu A, and flu B in a single test. It is manufactured by Abbott Laboratories which is a leading medical device and health care company.

1 INTRODUCTION

1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP-DOWN APPROACH
2.1 RESEARCH FLOW
2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET OVERVIEW
3.2 GLOBAL INFLUENZA DIAGNOSTICS ABSOLUTE MARKET OPPORTUNITY
3.3 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY REGION
3.4 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY PRODUCT
3.5 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY END-USER
3.6 GLOBAL INFLUENZA DIAGNOSTICS MARKET ATTRACTIVENESS, BY TEST TYPE
3.7 GLOBAL INFLUENZA DIAGNOSTICS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT (USD MILLION)
3.9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER (USD MILLION)
3.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (USD MILLION)
3.11 FUTURE MARKET OPPORTUNITIES
3.12 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

4.1 GLOBAL INFLUENZA DIAGNOSTICS MARKET EVOLUTION
4.2 GLOBAL INFLUENZA DIAGNOSTICS MARKET OUTLOOK
4.3 MARKET DRIVERS
- 4.3.1 GROWTH IN INFLUENZA RESEARCH FOR DIAGNOSTIC TECHNOLOGIES
- 4.3.2 RISE IN PREVALENCE OF INFLUENZA
4.4 RESTRAINTS
- 4.4.1 UNSKILLED PROFESSIONALS
- 4.4.2 STRINGENT FDA REGULATIONS
4.5 OPPORTUNITIES
- 4.5.1 ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES
- 4.5.2 INCREASE IN THE NUMBER OF RESEARCH AND DEVELOPMENT ACTIVITIES
4.6 IMPACT OF COVID-19 ON THE GLOBAL INFLUENZA DIAGNOSTICS MARKET
4.7 PORTER'S FIVE FORCES ANALYSIS
- 4.7.1 BARGAINING POWER OF BUYERS
- 4.7.2 BARGAINING POWER OF SUPPLIERS
- 4.7.3 THREAT OF SUBSTITUTES
- 4.7.4 THREAT FROM NEW ENTRANTS
- 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
4.8 VALUE CHAIN ANALYSIS
4.9 MACROECONOMIC ANALYSIS

5 MARKET, BY END-USER

5.1 OVERVIEW
5.1 DIAGNOSTIC LABORATORIES
5.2 HOSPITALS AND CLINICS
5.3 OTHERS

6 MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 TEST KIT AND REAGENTS
6.3 INSTRUMENTS
6.4 OTHERS

7 MARKET, BY TEST TYPE

7.1 OVERVIEW
7.2 TRADITIONAL DIAGNOSTIC TEST
- 7.2.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
- 7.2.2 VIRAL CULTURE
- 7.2.3 DIRECT FLUORESCENT ANTIBODY (DFA) TEST
- 7.2.4 SEROLOGICAL ASSAY
7.3 MOLECULAR DIAGNOSTIC ASSAY
- 7.3.1 RT-PCR
- 7.3.2 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TEST
- 7.3.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
- 7.3.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
- 7.3.5 OTHER MOLECULAR DIAGNOSTIC ASSAYS

8 MARKET, BY GEOGRAPHY

8.1 OVERVIEW
8.2 NORTH AMERICA
- 8.2.1 NORTH AMERICA MARKET SNAPSHOT
- 8.2.2 U.S.
- 8.2.3 CANADA
- 8.2.4 MEXICO
8.3 EUROPE
- 8.3.1 EUROPE MARKET SNAPSHOT
- 8.3.2 GERMANY
- 8.3.3 U.K.
- 8.3.4 FRANCE
- 8.3.5 ITALY
- 8.3.6 SPAIN
- 8.3.7 REST OF EUROPE
8.4 ASIA PACIFIC
- 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
- 8.4.2 CHINA
- 8.4.3 JAPAN
- 8.4.4 INDIA
- 8.4.5 REST OF ASIA PACIFIC
8.5 LATIN AMERICA
- 8.5.1 LATIN AMERICA MARKET SNAPSHOT
- 8.5.2 BRAZIL
- 8.5.3 ARGENTINA
- 8.5.4 REST OF LATIN AMERICA
8.6 MIDDLE EAST AND AFRICA
- 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
- 8.6.2 UAE
- 8.6.3 SAUDI ARABIA
- 8.6.4 SOUTH AFRICA
- 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW
9.2 COMPETITIVE SCENARIO
9.3 COMPANY MARKET RANKING ANALYSIS
9.4 COMPANY REGIONAL FOOTPRINT
9.5 COMPANY INDUSTRY FOOTPRINT
9.6 ACE MATRIX
- 9.6.1 ACTIVE
- 9.6.2 CUTTING EDGE
- 9.6.3 EMERGING
- 9.6.4 INNOVATORS

10 COMPANY PROFILES

10.1 ABBOTT LABORATORIES
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 COMPANY INSIGHTS
- 10.1.3 SEGMENT BREAKDOWN
- 10.1.4 PRODUCT BENCHMARKING
- 10.1.5 KEY DEVELOPMENTS
- 10.1.6 WINNING IMPERATIVES
- 10.1.7 CURRENT FOCUS & STRATEGIES
- 10.1.8 THREAT FROM COMPETITION
- 10.1.9 SWOT ANALYSIS
10.2 THERMO FISHER SCIENTIFIC INC.
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 COMPANY INSIGHTS
- 10.2.3 SEGMENT BREAKDOWN
- 10.2.4 PRODUCT BENCHMARKING
- 10.2.5 KEY DEVELOPMENTS
- 10.2.6 WINNING IMPERATIVES
- 10.2.7 CURRENT FOCUS & STRATEGIES
- 10.2.8 THREAT FROM COMPETITION
- 10.2.9 SWOT ANALYSIS
10.3 DANAHER CORPORATION
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 COMPANY INSIGHTS
- 10.3.3 SEGMENT BREAKDOWN
- 10.3.4 PRODUCT BENCHMARKING
- 10.3.5 WINNING IMPERATIVES
- 10.3.6 CURRENT FOCUS & STRATEGIES
- 10.3.7 THREAT FROM COMPETITION
- 10.3.8 SWOT ANALYSIS
10.4 SIEMENS HEALTHINEERS AG
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 COMPANY INSIGHTS
- 10.4.3 SEGMENT BREAKDOWN
- 10.4.4 PRODUCT BENCHMARKING
- 10.4.5 KEY DEVELOPMENTS
- 10.4.6 WINNING IMPERATIVES
- 10.4.7 CURRENT FOCUS & STRATEGIES
- 10.4.8 THREAT FROM COMPETITION
- 10.4.9 SWOT ANALYSIS
10.5 HOFFMANN-LA ROCHE AG
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 COMPANY INSIGHTS
- 10.5.3 SEGMENT BREAKDOWN
- 10.5.4 PRODUCT BENCHMARKING
- 10.5.5 KEY DEVELOPMENTS
- 10.5.6 WINNING IMPERATIVES
- 10.5.7 CURRENT FOCUS & STRATEGIES
- 10.5.8 THREAT FROM COMPETITION
- 10.5.9 SWOT ANALYSIS
10.6 BECTON, DICKINSON, AND COMPANY
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 COMPANY INSIGHTS
- 10.6.3 SEGMENT BREAKDOWN
- 10.6.4 PRODUCT BENCHMARKING
- 10.6.5 KEY DEVELOPMENTS
10.7 DIASORIN & LUMINEX CORPORATION
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 COMPANY INSIGHTS
- 10.7.3 SEGMENT BREAKDOWN
- 10.7.4 PRODUCT BENCHMARKING
- 10.7.5 KEY DEVELOPMENTS
- 10.7.6 LUMINEX CORPORATION COMPANY OVERVIEW
- 10.7.7 PRODUCT BENCHMARKING
10.8 QUIDEL CORPORATION
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 COMPANY INSIGHTS
- 10.8.3 SEGMENT BREAKDOWN
- 10.8.4 PRODUCT BENCHMARKING
- 10.8.5 KEY DEVELOPMENTS
10.9 CORIS BIOCONCEPT
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 COMPANY INSIGHTS
- 10.9.3 PRODUCT BENCHMARKING
10.1 ANALYTIK JENA AG (ENDRESS+HAUSER AG)
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 COMPANY INSIGHTS
- 10.10.3 SEGMENT BREAKDOWN
- 10.10.4 PRODUCT BENCHMARKING
10.11 MERIDIAN BIOSCIENCE
- 10.11.1 COMPANY OVERVIEW
- 10.11.2 COMPANY INSIGHTS
- 10.11.3 SEGMENT BREAKDOWN
- 10.11.4 PRODUCT BENCHMARKING
10.12 SA SCIENTIFIC, LTD
- 10.12.1 COMPANY OVERVIEW
- 10.12.2 COMPANY INSIGHTS
- 10.12.3 PRODUCT BENCHMARKING
10.13 SEKISUI DIAGNOSTIC
- 10.13.1 COMPANY OVERVIEW
- 10.13.2 COMPANY INSIGHTS
- 10.13.3 PRODUCT BENCHMARKING
- 10.13.4 KEY DEVELOPMENTS
10.14 HOLOGIC INC.
- 10.14.1 COMPANY OVERVIEW
- 10.14.2 COMPANY INSIGHTS
- 10.14.3 SEGMENT BREAKDOWN
- 10.14.4 PRODUCT BENCHMARKING
- 10.14.5 KEY DEVELOPMENTS
10.15 3M
- 10.15.1 COMPANY OVERVIEW
- 10.15.2 COMPANY INSIGHTS
- 10.15.3 SEGMENT BREAKDOWN
- 10.15.4 PRODUCT BENCHMARKING
10.16 BIOMERIEUX SA
- 10.16.1 COMPANY OVERVIEW
- 10.16.2 COMPANY INSIGHTS
- 10.16.3 SEGMENT BREAKDOWN
- 10.16.4 PRODUCT BENCHMARKING
10.17 GENMARK DIAGNOSTICS INC.
- 10.17.1 COMPANY OVERVIEW
- 10.17.2 COMPANY INSIGHTS
- 10.17.3 PRODUCT BENCHMARKING
10.18 ALTONA DIAGNOSTICS
- 10.18.1 COMPANY OVERVIEW
- 10.18.2 COMPANY INSIGHTS
- 10.18.3 PRODUCT BENCHMARKING
- 10.18.4 KEY DEVELOPMENT
10.19 ELITECH GROUP
- 10.19.1 COMPANY OVERVIEW
- 10.19.2 COMPANY INSIGHTS
- 10.19.3 PRODUCT BENCHMARKING
10.2 MAST GROUP LTD
- 10.20.1 COMPANY OVERVIEW
- 10.20.2 COMPANY INSIGHTS
- 10.20.3 PRODUCT BENCHMARKING
10.21 KONINKLIJKE PHILIPS N.V.
- 10.21.1 COMPANY OVERVIEW
- 10.21.2 COMPANY INSIGHTS
- 10.21.3 SEGMENT BREAKDOWN
- 10.21.4 PRODUCT BENCHMARKING
10.22 SYSMEX CORPORATION
- 10.22.1 COMPANY OVERVIEW
- 10.22.2 COMPANY INSIGHTS
- 10.22.3 SEGMENT BREAKDOWN
- 10.22.4 PRODUCT BENCHMARKING